ATM Mutation in Cancer: Context Before Conclusions
If ATM has appeared in your genetic or tumour reports, this article explains what ATM mutation in cancer really means, how it relates to MMR and BRCA1/2, and why biological context matters far more than the gene name alone.
Cholangiocarcinoma Patient – Lisa Craine
Cholangiocarcinoma patient - Lisa Craine. Lisa speaks at the 2017 [...]
HER2 Biliary Cancer: ERBB2 & Enhertu Explained
Learn how ERBB2 mutations lead to HER2 overexpression, why it appears more in distal bile ducts and gallbladder cancers, and how Enhertu targets it with precision.
Cholangiocarcinoma Australia Webinar Review 2025
Full review of the Cholangiocarcinoma Foundation Australia’s 2025 webinar. Key insights on genomic profiling, treatment gaps, and steps to national care standards.
FGFR2 Fusion The Fourth Domino
FGFR2 fusion isn't the start—it’s the tipping point. Understand how it transforms duct damage into cancer, and the steps you can take now to respond.
FGFR2 Mutation Drives Cholangiocarcinoma
FGFR2 mutation drives cholangiocarcinoma by trigger nonstop cell growth by fusing two genes into a rogue hybrid. This article explains how the mutation forms, what goes wrong, and how therapies like Pemigatinib and Futibatinib work to shut down the chaos and restore balance.
ATM Mutation in Cancer: Context Before Conclusions
If ATM has appeared in your genetic or tumour reports, this article explains what ATM mutation in cancer really means, how it relates to MMR and BRCA1/2, and why biological context matters far more than the gene name alone.
Cholangiocarcinoma Patient – Lisa Craine
Cholangiocarcinoma patient - Lisa Craine. Lisa speaks at the 2017 [...]
HER2 Biliary Cancer: ERBB2 & Enhertu Explained
Learn how ERBB2 mutations lead to HER2 overexpression, why it appears more in distal bile ducts and gallbladder cancers, and how Enhertu targets it with precision.
Cholangiocarcinoma Australia Webinar Review 2025
Full review of the Cholangiocarcinoma Foundation Australia’s 2025 webinar. Key insights on genomic profiling, treatment gaps, and steps to national care standards.
FGFR2 Fusion The Fourth Domino
FGFR2 fusion isn't the start—it’s the tipping point. Understand how it transforms duct damage into cancer, and the steps you can take now to respond.
FGFR2 Mutation Drives Cholangiocarcinoma
FGFR2 mutation drives cholangiocarcinoma by trigger nonstop cell growth by fusing two genes into a rogue hybrid. This article explains how the mutation forms, what goes wrong, and how therapies like Pemigatinib and Futibatinib work to shut down the chaos and restore balance.
